Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Journal Articles Current Opinion in Chemical Biology Year : 2014

Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer.

Abstract

The use of interleukin-2 (IL-2) for the stimulation of an effector immune response against metastatic cancer dates back to the early 1980s. Administration of unmodified IL-2, either alone or together with antigen-specific approaches, has resulted in remarkably long-term survival of some patients suffering from metastatic melanoma. However, such treatment is usually hampered by the appearance of toxic adverse effects, which has motivated the engineering of modified IL-2 formulations showing reduced toxicity while being more potent at stimulating anti-tumor effector immune cells. In this review we summarize and discuss the features and biological relevance of several enhanced IL-2 formulations, compare these to IL-15-based therapeutics, and try to foreshadow their potential in immunological research and immunotherapy.
Fichier principal
Vignette du fichier
COChembiol%20IL-2%20review%2013022015%20final%20version_to%20Miro%20Raeber_ZORA.pdf (385.96 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-02637735 , version 1 (19-08-2024)

Identifiers

Cite

Rodney A. Rosalia, Natalia Arenas-Ramirez, Gregory Bouchaud, Miro E. Raeber, Onur Boyman. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer.. Current Opinion in Chemical Biology, 2014, 23, pp.39-46. ⟨10.1016/j.cbpa.2014.09.006⟩. ⟨hal-02637735⟩

Collections

INRA INRAE
22 View
4 Download

Altmetric

Share

More